

Najat C Daw

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5717920/publications.pdf>

Version: 2024-02-01

43
papers

1,421
citations

331538

21
h-index

345118

36
g-index

44
all docs

44
docs citations

44
times ranked

2053
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients. <i>Oncotarget</i> , 2022, 13, 521-533.	0.8	4
2	White paper: Oncofertility in pediatric patients with Wilms tumor. <i>International Journal of Cancer</i> , 2022, , .	2.3	5
3	The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. <i>Nature Communications</i> , 2022, 13, .	5.8	14
4	Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. <i>Nature Biotechnology</i> , 2022, 40, 1624-1633.	9.4	31
5	Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. <i>Cell Reports</i> , 2021, 34, 108678.	2.9	33
6	Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. <i>Cancer Gene Therapy</i> , 2021, 28, 1325-1338.	2.2	13
7	Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. <i>Frontiers in Oncology</i> , 2021, 11, 625707.	1.3	7
8	A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3037-3049.	1.0	2
9	Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 978-985.	2.3	26
10	Prognostic Value of Cell-Surface Vimentin-Positive CTCs in Pediatric Sarcomas. <i>Frontiers in Oncology</i> , 2021, 11, 760267.	1.3	5
11	Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience. <i>Cancers</i> , 2020, 12, 2927.	1.7	12
12	A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children's Oncology Group AREN0321 study. <i>Cancer</i> , 2020, 126, 5156-5164.	2.0	19
13	Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1558-1568.	0.8	50
14	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. <i>Cancers</i> , 2020, 12, 1768.	1.7	20
15	Immuno-genomic landscape of osteosarcoma. <i>Nature Communications</i> , 2020, 11, 1008.	5.8	143
16	Aerosolized Chemotherapy for Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1257, 67-73.	0.8	6
17	Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study. <i>European Journal of Cancer</i> , 2019, 118, 58-66.	1.3	32
18	Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3802-3810.	3.2	42

#	ARTICLE	IF	CITATIONS
19	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 1-6.	0.9	60
20	Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. <i>Radiology</i> , 2018, 287, 303-312.	3.6	25
21	Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. <i>Oncologist</i> , 2018, 23, 360-366.	1.9	36
22	Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1315-1323.	1.9	13
23	¹⁸ F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 25-30.	2.8	39
24	Health-Related Quality of Life and Survival Outcomes of Pediatric Patients With Nonmetastatic Osteosarcoma Treated in Countries With Different Resources. <i>Journal of Global Oncology</i> , 2018, 4, 1-11.	0.5	1
25	Tumor thrombus in the large veins draining primary pelvic osteosarcoma on cross sectional imaging. <i>European Journal of Radiology</i> , 2018, 105, 49-55.	1.2	13
26	Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. <i>Clinical Cancer Research</i> , 2018, 24, 4865-4873.	3.2	68
27	Multi-level otsu method to define metabolic tumor volume in positron emission tomography. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 8, 373-386.	1.0	1
28	PET/CT of Osteosarcoma and Ewing Sarcoma. <i>Seminars in Roentgenology</i> , 2017, 52, 255-268.	0.2	14
29	A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. <i>International Journal of Cancer</i> , 2017, 141, 1469-1477.	2.3	42
30	Prospective study of neuropathic pain after definitive surgery for extremity osteosarcoma in a pediatric population. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26162.	0.8	19
31	Ewing sarcoma family of tumors in children younger than 10 years of age. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26275.	0.8	14
32	¹⁸ F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone. <i>Journal of Cancer</i> , 2017, 8, 2892-2898.	1.2	27
33	Local Control Modality and Outcome for Ewing Sarcoma of the Femur: A Report From the Children's Oncology Group. <i>Annals of Surgical Oncology</i> , 2016, 23, 3541-3547.	0.7	8
34	A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1761-1770.	0.8	71
35	Comparison of ¹⁸ F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1381-1386.	0.8	81
36	IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw182.	3.0	49

#	ARTICLE	IF	CITATIONS
37	Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 148-160.	1.1	38
38	Cardiovascular involvement by osteosarcoma: an analysis of 20 patients. <i>Pediatric Radiology</i> , 2016, 46, 21-33.	1.1	27
39	Prognostic Factors and Patterns of Relapse in Ewing Sarcoma Patients Treated With Chemotherapy and R0 Resection. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 349-357.	0.4	23
40	Influence of bony resection margins and surgicopathological factors on outcomes in limb-sparing surgery for extremity osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 246-251.	0.8	32
41	Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing. <i>Clinical Cancer Research</i> , 2014, 20, 2783-2792.	3.2	37
42	Photons or Protons for Non-Central Nervous System Solid Malignancies in Children: A Historical Perspective and Important Highlights. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e354-e359.	1.8	3
43	Analysis of prognostic factors in ewing sarcoma family of tumors. <i>Cancer</i> , 2007, 110, 375-384.	2.0	211